research on glp 1 drugs GLP-1 Market Size to Hit USD 132.79 Bn by 2035 Discovery of GLP-1–Based Drugs for

2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.

Liposomal Berberine for Enhanced Absorption: GLP-1 Support Berberine Weight Loss support utilizes a liposomal delivery system designed to improve the absorption and bioavailability of Berberine

Use of glucagon-like peptide 1 agonists for weight loss compared with bupropion-naltrexone was associated with an increased risk for pancreatitis, gastroparesis and bowel obstruction but not biliary disease, researchers reported in JAMA

If you are preparing for surgery, one of the most important safety steps is to inform your surgeon and anesthesia team if you are taking a GLP-1 medication

Purpose of Review This review summarizes the current understanding of the physiologic influence of GLP-1 RAs on gastrointestinal motility, highlights key clinical implications of these effects, and defines areas for future investigation

Available via online consultation with nationwide delivery from Yuushin Clinic, Sapporo.